Morgan Stanley set a $86.00 target price on Eli Lilly and Company (NYSE:LLY) in a research note released on Friday. The brokerage currently has a hold rating on the stock.

Other research analysts have also issued reports about the company. Berenberg Bank reiterated a buy rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Friday, August 4th. Oppenheimer Holdings, Inc. lowered Eli Lilly and from an outperform rating to a market perform rating and set a $90.00 price objective for the company. in a research report on Wednesday, July 26th. BMO Capital Markets reiterated an underperform rating and issued a $73.00 price objective on shares of Eli Lilly and in a research report on Wednesday, July 26th. Jefferies Group LLC reiterated a buy rating and issued a $89.00 price objective on shares of Eli Lilly and in a research report on Thursday, August 31st. Finally, Leerink Swann lowered Eli Lilly and from an outperform rating to a market perform rating and lowered their price objective for the stock from $93.00 to $90.00 in a research report on Wednesday, July 26th. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The company has a consensus rating of Hold and an average target price of $88.42.

Shares of Eli Lilly and (LLY) opened at 87.08 on Friday. The company’s 50 day moving average price is $82.21 and its 200-day moving average price is $82.15. Eli Lilly and has a 52 week low of $64.18 and a 52 week high of $89.09. The company has a market capitalization of $91.87 billion, a price-to-earnings ratio of 37.68 and a beta of 0.34.

Eli Lilly and (NYSE:LLY) last issued its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping the consensus estimate of $1.05 by $0.06. The company had revenue of $5.82 billion during the quarter, compared to analyst estimates of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The firm’s revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the business posted $0.86 earnings per share. Analysts anticipate that Eli Lilly and will post $4.16 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Morgan Stanley Reiterates “$86.00” Price Target for Eli Lilly and Company (LLY)” was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/09/morgan-stanley-reiterates-86-00-price-target-for-eli-lilly-and-company-lly.html.

In other news, major shareholder Lilly Endowment Inc sold 205,000 shares of the firm’s stock in a transaction on Wednesday, October 4th. The stock was sold at an average price of $86.81, for a total transaction of $17,796,050.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last 90 days, insiders have sold 990,000 shares of company stock valued at $82,949,650. Company insiders own 0.20% of the company’s stock.

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Eqis Capital Management Inc. raised its stake in shares of Eli Lilly and by 25.4% in the third quarter. Eqis Capital Management Inc. now owns 10,387 shares of the company’s stock valued at $888,000 after acquiring an additional 2,105 shares in the last quarter. Curbstone Financial Management Corp raised its stake in shares of Eli Lilly and by 101.1% in the third quarter. Curbstone Financial Management Corp now owns 13,688 shares of the company’s stock valued at $1,171,000 after acquiring an additional 6,883 shares in the last quarter. MPS Loria Financial Planners LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at $128,000. W. E. Donoghue & Co. LLC acquired a new stake in shares of Eli Lilly and in the second quarter valued at $16,220,000. Finally, M Holdings Securities Inc. acquired a new stake in shares of Eli Lilly and in the second quarter valued at $234,000. Institutional investors and hedge funds own 75.72% of the company’s stock.

About Eli Lilly and

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Analyst Recommendations for Eli Lilly and (NYSE:LLY)

Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.